Status
Conditions
About
Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures
Objectives
Study design One academic center, prospective, diagnostic study
Research Methodology Target population: Patients who are diagnosed malignant biliary stricture. Sample population: Patients who are diagnosed malignant biliary stricture in Chulalongkorn Hospital
Full description
Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures
Objectives
Study design One academic center, prospective, diagnostic study
Research Methodology Target population: Patients who are diagnosed malignant biliary stricture. Sample population: Patients who are diagnosed malignant biliary stricture in Chulalongkorn Hospital
Inclusion Criteria
1.Cannot follow up for 1 year 2.Bleeding tendency including decompensated cirrhosis, chronic kidney disease and long-tem antiplatelets or anticoagulants 3.Pregnancy 4.History of fluorescein allergy
Timeline: From January 2012 to December 2013
Sample size Due to no study in Thai population before, investigator will perform pilot study in 50 malignant biliary stricture patients
Method
4.Set confocal endomicroscopy at the same session of ERCP 5.After successfully cannulation;
10% Fluorescein sodium 2.5 ml was injected intravenously.
Confocal endomicroscopy (CholangioFlex) was performed at the suspected area. The video will record the images with Cellvizio program recorder.
6.Brush cytology was performed 7.Record the duration and complication of the procedure 8.Send the tissues to one clinically-blinded GI pathologist for pathological diagnosis and FISH test 9.Compare the pathology and FISH report and endoscopic finding 10.Report the result According to Miami-criteria 2009, the Criteria for malignant biliary stricture from CholangioFlex are one of the followings;
Thick branching bands (>20 microns)
Dark clumps or glands (usually measuring > 60 microns)
Bright and tortuous vessels
Follow up
The patients who are diagnosed malignant biliary obstruction will be treated as standard management
The patients who are not diagnosed malignant biliary obstruction will be followed up every 3 months for 1 year
The gold standard is pathology or clinical of malignancy including evidence of metastasis.
Statistical analysis Sensitivity, specificity, negative predictive value(NPV), positive predictive value(PPV) and accuracy by McNemar's test
Ethical considerations There is not a clearly evidence about the significant serious side effect of fluorescein injection. If the patients have side effects during the research, the procedure will be terminated and the patients will be in the responsibility of all investigators.
Expected benefit and application
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
5 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal